Andrew Allen - Jul 1, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role
Director, 10%+ Owner
Signature
/s/ Andrew R. Allen; By: Mary Christina Thomson, Attorney-In-Fact
Stock symbol
SRRA
Transactions as of
Jul 1, 2022
Transactions value $
-$90,750
Form type
4
Date filed
7/1/2022, 04:38 PM
Previous filing
Apr 20, 2022
Next filing
Dec 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRRA Common Stock Disposed to Issuer -$90.8K -1.65K -100% $55.00 0 Jul 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -750 -100% $0.00* 0 Jul 1, 2022 Common Stock 750 $26.40 Direct F1, F2
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -1.25K -100% $0.00* 0 Jul 1, 2022 Common Stock 1.25K $76.80 Direct F3, F4
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -625 -100% $0.00* 0 Jul 1, 2022 Common Stock 625 $130.80 Direct F4, F5
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -12K -100% $0.00* 0 Jul 1, 2022 Common Stock 12K $13.98 Direct F2, F6
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -6K -100% $0.00* 0 Jul 1, 2022 Common Stock 6K $18.11 Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Andrew Allen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The option fully vested on July 11, 2020.
F2 Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
F3 The option fully vested on November 10, 2018.
F4 Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
F5 The option fully vested on June 12, 2019.
F6 The option fully vested on June 9, 2021.
F7 The option fully vested on June 8, 2022.